Literature DB >> 27536162

Adrenal insufficiency presenting as hypercalcemia and acute kidney injury.

Seung Won Ahn1, Tong Yoon Kim1, Sangmin Lee1, Jeong Yeon Jeong1, Hojoon Shim1, Yu Min Han1, Kyu Eun Choi1, Seok Joon Shin2, Hye Eun Yoon2.   

Abstract

Adrenal insufficiency is an uncommon cause of hypercalcemia and not easily considered as an etiology of adrenal insufficiency in clinical practice, as not all cases of adrenal insufficiency manifest as hypercalcemia. We report a case of secondary adrenal insufficiency presenting as hypercalcemia and acute kidney injury in a 66-year-old female. The patient was admitted to the emergency department with general weakness and poor oral intake. Hypercalcemia (11.5 mg/dL) and moderate renal dysfunction (serum creatinine 4.9 mg/dL) were shown in her initial laboratory findings. Studies for malignancy and hyperparathyroidism showed negative results. Basal cortisol and adrenocorticotropic hormone levels and adrenocorticotropic hormone stimulation test confirmed the diagnosis of adrenal insufficiency. With the administration of oral hydrocortisone, hypercalcemia was dramatically resolved within 3 days. This case shows that adrenal insufficiency may manifest as hypercalcemia and acute kidney injury, which implicates that adrenal insufficiency should be considered a cause of hypercalcemia in clinical practice.

Entities:  

Keywords:  acute kidney injury; adrenal insufficiency; hypercalcemia

Year:  2016        PMID: 27536162      PMCID: PMC4973717          DOI: 10.2147/IMCRJ.S109840

Source DB:  PubMed          Journal:  Int Med Case Rep J        ISSN: 1179-142X


Introduction

Hypercalcemia is a common disease found in emergency departments and in-patients. Although primary hyperparathyroidism and malignancy are the most common causes of hypercalcemia, adrenal insufficiency is a rare but important cause of hypercalcemia.1 As not all cases of adrenal insufficiency present with hypercalcemia, adrenal insufficiency is not easily considered an etiology of hypercalcemia. The prevalence of hypercalcemia at the time of diagnosis of Addison’s disease is reported to be ~5.5%–6.0%.2 Previous studies have reported hypercalcemia associated with adrenal insufficiency; however, hypercalcemia and acute kidney injury (AKI) related with adrenal insufficiency is rarely reported. Here, we report a case of adrenal insufficiency that presented as hypercalcemia and AKI.

Case presentation

A 66-year-old female presented to the emergency department with 1 week duration of general weakness and poor oral intake. She had an underlying disease of diabetes and hypertension for 10 years and had been treated with medications at the local clinic, which included metformin, glimepiride, hydrochlorothiazide, losartan, and atorvastatin. She also had severe osteoarthritis at both knee joints and had multiple steroid injections at the local orthopedic clinic. Approximately 2 weeks before admission, she had been admitted for treatment of urinary tract infection (UTI). At that time, blood culture and urine culture showed growth of Escherichia coli and was treated with ceftriaxone and tazobactam. She was not on any antihypertensive medication for 2 weeks. Physical examination showed the following findings: height 152 cm, body weight 57 kg, blood pressure 70/50 mmHg, heart rate 70 beats per minute, and respiratory rate 20 per minute, with body temperature 36.5°C. Decreased skin and tongue turgor were observed. Pulmonary, cardiac, abdominal, and neurologic examinations were unremarkable. Table 1 shows the laboratory data at admission and those 2 weeks before admission. Her outpatient laboratory data checked at 2 weeks prior to admission showed normal levels of serum creatinine and calcium. Serum magnesium level decreased to a lower limit of normal range at admission. Fractional excretion of sodium was 1.0%.
Table 1

Laboratory data on admission and 2 weeks before

VariableReference rangeOn admissionTwo weeks before
Hematocrit (%)40.0–48.039.734.4
Hemoglobin (g/dL)13.0–18.013.711.7
White cell count (109/L)4.0–10.013.06.71
Differential count (%)
 Neutrophils45–7536.039.2
 Lymphocytes20–5039.641.6
 Monocytes2–917.511.6
 Eosinophils0–55.56.6
 Basophils0–21.41.0
 Platelet (109/L)140–450350530
 Sodium (mmol/L)135–145132140
 Potassium (mmol/L)3.5–5.53.43.5
 Chloride (mmol/L)98–11096105
 Urea nitrogen (mg/dL)6.0–20.037.913.0
 Creatinine (mg/dL)0.68–1.304.90.6
MDRD-GFR (mL/minutes/1.73 m2)9.6693.64
Calcium (mg/dL)8.6–10.211.59.4
Phosphorus (mg/dL)2.7–4.53.64.1
Magnesium (mg/dL)1.6–2.61.62.0
Total bilirubin (mg/dL)<1.01.00.6
Aspartate aminotransferase (U/L)0–402013
Alanine aminotransferase (U/L)0–401616
Total protein (g/dL)6.6–8.75.96.0
Albumin (g/dL)3.4–4.82.82.9
Urinalysis
 Specific gravity1.003–1.0301.016
 pH4.8–7.55.0
 ProteinNegativeNegative
 GlucoseNegativeNegative
 KetoneNegativeNegative
 NitriteNegativeNegative
 BilirubinNegativeNegative
 BloodNegativeNegative
 Microscopic white blood cell0–3/HPF20–29/HPF
 Microscopic red blood cell0–1/HPF5–9/HPF
 Epithelial cell0–1/HPF1–4/HPF
 Urine bacteriaNegativeSome

Abbreviations: HPF, high power field; MDRD-GFR, modification of diet in renal disease–glomerular filtration rate.

Having pyuria and hypotension, with a previous history of UTI, she was first diagnosed as UTI sepsis. She was admitted to the intensive care unit and antibiotics and massive hydration (30 mL/kg of crystalloids) were administered. The patient’s vital signs were stabilized after administration of crystalloids. Within 2 days, inflammatory signs and blood pressure were normalized. However, serum calcium and creatinine levels remained elevated, and the patient constantly complained about poor oral intake and general weakness. On the third hospital day, administration of saline and calcitonin (40 IU per day) was begun. Serum calcium level decreased for the next 2 days (from 11.9 to 9.9 mg/dL) but began to increase again from the third day of calcitonin administration. To evaluate the cause of hypercalcemia, contrast-enhanced computed tomography of chest and abdomen and whole body bone scintigraphy were performed, but the results showed no evidence of malignancy. Serum and urine protein electrophoresis, anti-neutrophil cytoplasmic antibody titers, and tumor marker studies were negative. Thyroid function profile revealed normal levels of thyroid stimulating hormone (0.68 μIU/L, normal range: 0.34–0.56 μIU/L) and free thyroxine (1.12 ng/dL, normal range: 0.58–1.64 ng/dL). The bone mineral density T-score was –1.4, which indicated osteopenia. Intact parathyroid hormone (PTH) was 7.5 pg/mL (normal range: 12–88 pg/mL), PTH-related peptide was undetectable (normal range: <1.1 pmol/L), and serum 25-hydroxy vitamin D was 16.32 ng/mL (normal range: 30–100 ng/mL). These results indicated a suppressed PTHvitamin D axis. We found that the patient had multiple steroid injections in both her knee joints in the past, although the amount of steroid could not be quantified. Adrenocortical function was assessed, and showed that her serum cortisol level was 2.36 μg/dL and adrenocorticotropic hormone (ACTH) was 32.51 pg/mL (normal range: 10–60 pg/mL). The ACTH stimulation test showed inadequate cortisol response to the pharmacological dose of ACTH (Table 2). As most people with secondary adrenal insufficiency fall within the range limit and usually below 35, the plasma ACTH level and ACTH stimulation test results suggested the diagnosis of secondary adrenal insufficiency.3 Hydrocortisone (1.5 mg/kg) was administered from the tenth hospital day. Her serum calcium level returned to normal within 3 days and her general weakness and anorexia were completely improved (Figure 1). With the normalization of calcium level, magnesium level trended toward normal range. After 2 weeks of follow-up, serum calcium level was maintained at 8.7 mg/dL. As the patient was at a high risk of developing osteoporosis and needed corticosteroid replacement, regular monitoring for bone mineral density was considered, but the patient was lost for follow-up.
Table 2

The ACTH stimulation test

Time (minutes)0306090120
Cortisol (μg/dL)2.369.3711.4312.8510.21

Note: Cortisol reference range (6.7–22.6 μg/dL).

Abbreviation: ACTH, adrenocorticotropic hormone.

Figure 1

Clinical course of serum calcium, magnesium, and creatinine level.

Discussion

Hypercalcemia is a common finding in patients in emergency and in-patients. Although hypercalcemia can be related with adrenal insufficiency, adrenal insufficiency is not easily considered a cause of hypercalcemia. In this case, thorough evaluation for malignancy and parathyroid disease failed to make the diagnosis, but a test for adrenocortical function demonstrated the cause of hypercalcemia and AKI, and glucocorticoid replacement resolved hypercalcemia. In this case, the patient had an unclear history of steroid injections. It was certain that the patient had multiple steroid injections in both her knee joints, but the amount of intra-articularly administered glucocorticoids could not be quantified. The prevalence of adrenal insufficiency secondary to locally applied glucocorticoids is not clear. According to one study, a single injection of intra-articularly administered glucocorticoids can cause adrenal suppression.4 The intra-articular injections of glucocorticoid medication might have interfered with normal pituitary function and caused secondary adrenal insufficiency. It is reported that the prevalence of hypercalcemia is ~5.5%–6.0% at the time of diagnosis of Addison’s disease.2 Previous studies have reported hypercalcemia associated with adrenal insufficiency; however, hypercalcemia and AKI related with adrenal insufficiency is rarely reported. The development of renal injury in individuals with hypercalcemia is related to the degree and duration of hypercalcemia. Long-standing hypercalcemia and hypercalciuria can lead to nephrogenic diabetes insipidus, nephrolithiasis, nephrocalcinosis, tubular atrophy with interstitial fibrosis and, thus, chronic kidney disease. Hypercalcemia can lead to a decrease in the glomerular filtration rate mediated by direct renal vasoconstriction and natriuresis-induced volume contraction.5,6 In this case, hypercalcemia can be the cause of AKI. However, the patient had hypotension and UTI at the arrival of emergency department and these could have had influence on the renal function. The fractional excretion of sodium was calculated to be 1% and in the urinary sediment, epithelial cells were present, which indicates that acute tubular necrosis may be present. Considering these results, in our opinion, the patient’s AKI was due to a mixture of prerenal (hypotension) and intrinsic (UTI sepsis and hypercalcemia) causes. Patients with hypercalcemia can develop mild hypomagnesemia. This is partially explained by the fact that calcium and magnesium functionally compete for transport in the thick ascending limb of the loop of Henle.7 In this case, the initial magnesium level was 1.6 mg/dL, which was at the lower borderline of the normal range. Although the PTH level was not checked after the normalization of calcium and magnesium level, considering the change in magnesium level along with calcium level, we speculate that hypercalcemia caused hypomagnesemia and that both hypercalcemia and hypomagnesemia suppressed the PTH level. Though the mechanism of hypercalcemia in adrenal insufficiency is unknown in detail, a number of mechanisms are thought to be the possible cause. First, adrenal insufficiency causes hypovolemia and a consequent reduction in glomerular infiltration rate. Decreased glomerular infiltration rate results in reduction in the amount of calcium filtered at the glomerulus, and increased calcium renal reabsorption in proximal tubule.8,9 Rehydration with normal saline will normalize the glomerular filtration rate as well as the level of filtered calcium. Second, the enzyme activity of 1-alpha-hydroxylase may be increased in adrenal insufficiency. The 1-alpha-hydroxylase is a renal enzyme that participates in conversion of calcidiol to the active form of vitamin D, calcitriol, leading to increased intestinal absorption of calcium.10 As prednisone inhibits 1-alpha-hydroxylase, thus reducing hypercalcemia, adrenal insufficiency may result in hypercalcemia. Third, a decrease in circulating stanniocalcin, a paracrine hormone secreted from the adrenal gland, could result in reduced levels of circulating calcium. Deficient adrenal hormone and decreased level of stanniocalcin may affect skeletal calcium efflux into circulation and result in hypercalcemia.11 In conclusion, this case shows that adrenal insufficiency may cause hypercalcemia, and it can present as hypotension and AKI. After excluding more common diseases, such as malignancy and primary hyperparathyroidism, the possibility of adrenal insufficiency should be considered the cause of hypercalcemia, especially in elderly patients with a history of glucocorticoid injection.
  11 in total

1.  Adrenal insufficiency secondary to inappropriate oral administration of topical exogenous steroids presenting with hypercalcaemia.

Authors:  Rahila Sarwar Bhatti; Michael D Flynn
Journal:  BMJ Case Rep       Date:  2012-06-21

Review 2.  Disorders involving calcium, phosphorus, and magnesium.

Authors:  Sharon M Moe
Journal:  Prim Care       Date:  2008-06       Impact factor: 2.907

Review 3.  The diagnosis and management of hypercalcaemia.

Authors:  Salvatore Minisola; Jessica Pepe; Sara Piemonte; Cristiana Cipriani
Journal:  BMJ       Date:  2015-06-02

Review 4.  Adrenal Insufficiency Caused by Locally Applied Glucocorticoids-Myth or Fact?

Authors:  Stina Willemoes Borresen; Marianne Klose; Ase Krogh Rasmussen; Ulla Feldt-Rasmussen
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

5.  Addison's disease--clinical studies. A report fo 108 cases.

Authors:  J Nerup
Journal:  Acta Endocrinol (Copenh)       Date:  1974-05

Review 6.  Clinical review: Rare causes of hypercalcemia.

Authors:  Thomas P Jacobs; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2005-08-30       Impact factor: 5.958

Review 7.  Physiological basis for the etiology, diagnosis, and treatment of adrenal disorders: Cushing's syndrome, adrenal insufficiency, and congenital adrenal hyperplasia.

Authors:  Hershel Raff; Susmeeta T Sharma; Lynnette K Nieman
Journal:  Compr Physiol       Date:  2014-04       Impact factor: 9.090

8.  Reversible renal failure due to isolated renal sarcoidosis.

Authors:  P F Williams; D Thomson; J L Anderton
Journal:  Nephron       Date:  1984       Impact factor: 2.847

9.  Isolated adrenocorticotropic hormone deficiency presenting with hypercalcemia in a patient on long-term hemodialysis.

Authors:  Akihiko Kato; Shingo Shinozaki; Takao Goga; Akira Hishida
Journal:  Am J Kidney Dis       Date:  2003-08       Impact factor: 8.860

10.  Opioid-induced secondary adrenal insufficiency presenting as hypercalcaemia.

Authors:  Angela S Lee; Stephen M Twigg
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2015-06-18
View more
  6 in total

Review 1.  Hypercalcemia: a consultant's approach.

Authors:  Ari Auron; Uri S Alon
Journal:  Pediatr Nephrol       Date:  2017-09-06       Impact factor: 3.714

Review 2.  Electrolyte and Acid-Base Disorders Associated with Cancer Immunotherapy.

Authors:  Nupur N Uppal; Biruh T Workeneh; Helbert Rondon-Berrios; Kenar D Jhaveri
Journal:  Clin J Am Soc Nephrol       Date:  2022-01-21       Impact factor: 10.614

3.  Evaluation of the Increase in Serum Calcium Levels After Unilateral Adrenalectomy.

Authors:  Mehmet Üstün; Korhan Tuncer
Journal:  Cureus       Date:  2022-09-13

4.  Disseminated histoplasmosis in India presenting as addisonian crisis with epiglottis involvement.

Authors:  Jatin Agrawal; Naresh Bansal; Anil Arora
Journal:  IDCases       Date:  2020-05-28

5.  Myrcene Attenuates Renal Inflammation and Oxidative Stress in the Adrenalectomized Rat Model.

Authors:  Azim Ullah Shamsul Islam; Björn Hellman; Fred Nyberg; Naheed Amir; Richard L Jayaraj; Georg Petroianu; Abdu Adem
Journal:  Molecules       Date:  2020-09-30       Impact factor: 4.411

Review 6.  Genetic causes of neonatal and infantile hypercalcaemia.

Authors:  Caroline M Gorvin
Journal:  Pediatr Nephrol       Date:  2021-05-14       Impact factor: 3.714

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.